Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Henri Becquerel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age superior to 18 years old
Patient undergoing maintenance treatment for Mantle Cell Lymphoma or Follicular Lymphoma treated with rituximab or obinutuzumab in complete remission or stable disease between injection #1 and injection #13 or 19 (end of second year or third year)
Inform consent signed
You may not be if
Documented history of SARS-Cov-2 infection less than 3 months old
Progressive lymphoma
Contraindication SARS-Cov-2 vaccination (allergy)
Refusal of SARS-CoV-2 vaccination
Patient who has been off rituximab or obinutuzumab therapy for more than 6 months
Patient not covered by health system
Pregnant or nursing woman
Clareo Health | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma
